A longer course of androgen deprivation therapy does not improve outcomes in patients with localized, high-risk prostate cancer receiving I-125 brachytherapy and external beam radiotherapy, a phase 3 trial suggests.
AAP and apalutamide may improve outcomes, compared with bicalutamide, in a subgroup of patients with prostate cancer receiving ADT and salvage radiation after radical prostatectomy, according to researchers.
Adding olaparib to first-line treatment with abiraterone extends overall survival in patients with metastatic castration-resistant prostate cancer, a phase 3 study suggests.
Adding niraparib to AAP improves rPFS in patients with BRCA-mutated metastatic castration-resistant prostate cancer, a phase 3 trial suggests.
Intensified ADT with apalutamide, with or without abiraterone plus prednisone, for 52 weeks prolonged PSA progression-free survival compared with ADT alone among men with high-risk biochemically recurrent prostate cancer following radical prostatectomy.
Rucaparib improves radiographic progression-free survival when compared with physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer, according to results from the TRITON3 trial.
Dietary counseling may improve clinical outcomes for men with prostate cancer.
Cytoreductive radical prostatectomy for newly diagnosed metastatic hormone-sensitive prostate cancer can be performed with minimal morbidity and is associated with a low risk for symptomatic local recurrence.
The higher risk for radiographic progression and death observed among older men taking abiraterone is likely due to more toxicity leading to more frequent and earlier drug discontinuation, according to investigators.
Nephron-sparing management is one strategy to reduce risks, according to investigators.
Please login or register first to view this content.
